Center of excellence

Cardiovascular Risk Reduction

ADVISORY BOARD

Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
Seth Baum, MD

Clinical Affiliate Professor of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University; President, Preventive Cardiology, Inc., Boca Raton, Florida

Dr Baum is a graduate of Columbia University College of Physicians and Surgeons and completed training in internal medicine, cardiology, interventional cardiology, and electrophysiology. He is a founding physician/scientist member of the Society of Cardiovascular Computed Tomography (SCCT), president of the American Society of Preventive Cardiology (ASPC), and sits on the American Heart Association Council on Epidemiology and Prevention. In 2013 he was awarded Cleveland Heart Lab's Heart Award for lifelong dedication to preventive medicine. Dr Baum is a clinical affiliate professor of biomedical science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and is president of Preventive Cardiology, Inc., in Boca Raton, Florida.

Disclosures

Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Akcea Therapeutics; Amgen; Gerson Lehrman Group; Guidepoint Global; Regeneron Pharmaceuticals; Sanofi; Novo Nordisk
Serve(d) as a speaker or a member of a speakers bureau for: Akcea Therapeutics; Amgen; Boehringer Ingelheim; Eli Lilly and Company; Novo Nordisk
Serve(d) on the scientific advisory board for: Akcea Therapeutics; Amgen; AstraZeneca; Esperion Therapeutics; Regeneron Pharmaceuticals; Sanofi; Novartis

Matthew J. Budoff, MD
Matthew J. Budoff, MD

Professor of Medicine, University of California, Los Angeles; Program Director, Department of Cardiology, Harbor UCLA Medical Center, Torrance, California

Dr Budoff has devoted much of his time over the past 25 years to advancing procedures that can help doctors identify cardiac patients early and place them on a therapeutic path to prevent heart attacks. Dr Budoff works on at least 20 active medical research trials at any given time and is a frequent lecturer on cardiology topics at symposia, congresses, and annual conferences globally. He has authored or coauthored over 800 research papers, seven books, and 45 book chapters.

Disclosures

Matthew J. Budoff, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Amarin Pharma Inc.
Received research grant from: General Electric; Amarin Pharma Inc.

Jay H. Shubrook, DO, FAAFP, FACOFP
Jay H. Shubrook, DO

Professor, Director of Clinical Research, Department of Primary Care, Touro University, Vallejo; Director of Diabetes Services, Solono County Family Health Services, Fairfield, California; Diabetologist, NorthBay Center for Diabetes & Endocrinology, Vacaville, California

Dr Shubrook is a board-certified family physician and fellowship-trained diabetologist. He is a professor and director of clinical research at the Touro College of Osteopathic Medicine in Vallejo, California, where he also serves as director of diabetes services. He provides clinical care at NorthBay Center for Diabetes & Endocrinology in Vacaville, California. He completed his medical and fellowship training at Heritage College of Osteopathic Medicine in Athens, Ohio. He serves as an associate editor to both Clinical Diabetes and the Journal of the American Osteopathic Association, and is on the editorial board of Medicine Matters: Diabetes. Dr Shubrook also chairs the American Diabetes Association's Primary Care Advisory Group.

Disclosures

Jay H. Shubrook, DO, FAAFP, FACOFP, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Novo Nordisk; Bayer; Sanofi.

Pam R. Taub, MD, FACC, FASPC
Pam R. Taub, MD

Associate Professor, UC San Diego School of Medicine, Department of Cardiovascular Medicine; Founding Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center, La Jolla, California

Dr Taub's clinical practice focuses on preventive cardiology and lipidology, as well as women's cardiovascular health. She has extensive clinical trial experience and is active in clinical and translational research. Her research focuses on assessing the impact of behavioral, technological, and pharmacologic interventions on cardiometabolic disease. Dr Taub is a federally funded researcher with funding from the National Institutes of Health (principal investigator on R01 grant), Department of Defense, Department of Homeland Security, and American Heart Association.

She is currently conducting research studies evaluating:

the impact of daily fasting on improving cardiometabolic parameters and on mitochondrial function
biomarkers for cardiovascular risk factor stratification
wearable/mobile devices in improving cardiovascular outcomes
epicatechin (compound in dark chocolate) on mitochondrial function/cellular bioenergetics and exercise capacity

Dr Taub is widely published and has authored numerous publications in top peer-reviewed journals, including Cell Metabolism, Journal of the American Medical Association, and Journal of the American College of Cardiology.

Dr Taub holds multiple leadership positions in professional societies, serving as a fellow and board member for the American Society of Preventive Cardiology. She is a fellow and member of the American College of Cardiology Prevention of CV Disease Section Leadership Council. She also serves on the American Heart Association Council on Clinical Cardiology (Women in Cardiology Committee).

Dr Taub received her MD from Boston University School of Medicine. She completed her residency in internal medicine at the University of Washington Medical Center in Seattle and her fellowship in cardiovascular medicine at UC San Diego. She is board certified in internal medicine, cardiovascular disease.

Disclosures

Pam R. Taub, MD, FACC, FASPC, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Esperion Therapeutics; Boehringer Ingelheim; Novo Nordisk; Amarin Corporation; Esperion Therapeutics, Inc.
Serve(d) as a shareholder for: Epirium Bio

The Cardiovascular Risk Reduction Center of Excellence is a collaboration between the American College of Cardiology and Medscape. Content developed through the partnership, with oversight from the Advisory Board, is labeled as a collaboration.